LIFYORLI (COPACKAGED) vs MVASI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 11, 2026·How we rate

Possible drug interaction. LIFYORLI (COPACKAGED) and MVASI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	LIFYORLI (COPACKAGED)	MVASI
Rating	New	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	RELACORILANT	BEVACIZUMAB-AWWB
Manufacturer	Corcept Therap	Amgen Inc
Dosage forms	Kit	Injectable
Drug class	—	—
Boxed warning	None	None
Treats	Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms, Peritoneal Neoplasms	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

lifyorli (copackaged)mvasi

Rating

New

72/100

Pharmacy pays

—

Type

Active ingredient

RELACORILANT

BEVACIZUMAB-AWWB

Manufacturer

Corcept Therap

Amgen Inc

Dosage forms

Kit

Injectable

Drug class

—

Boxed warning

None

Treats

Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Frequently asked questions

What is the difference between Lifyorli (Copackaged) and Mvasi?

Lifyorli (Copackaged) contains Relacorilant, while Mvasi contains Bevacizumab-Awwb — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.